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Only two HIV vaccines have been
taken through efficacy trials so far. In the
first HIV vaccine efficacy trial started ten
years ago, recombinant gp120 protein, the
CD4-binding subunit of the HIV enve-
lope, was used as vaccine antigen [1]. The
vaccine neither prevented HIV acquisition
nor reduced the viral load in those
acquiring HIV infection. Although the
vaccine was able to induce antibodies to
gp120, these did not neutralize field
isolates of HIV. Differences in the confor-
mation between the monomeric gp120
subunit of the vaccine and the functionally
active trimeric envelope spike on the
surface of virus particles, HIV diversity,
as well as various antibody escape mech-
anisms of the HIV envelope (reviewed in
[2]), have been proposed to explain the
inefficacy of the antibody-based gp120
vaccine. Given the difficulties of antibody-
based HIV prevention strategies, the
second HIV efficacy trial, the STEP study,
tested whether the second arm of the
adaptive immune response, cytotoxic T
cells, would be able to provide protection.
To induce cytotoxic T cell responses,
replication-deficient adenoviral vectors
transfering the gag, pol, and nef genes of
HIV were used. Since all the three vaccine
antigens used in this study are intracellular
proteins that are usually not expressed on
the surface of HIV-infected cells or HIV
particles, vaccine-induced HIV-specific
antibodies should not be able to contribute
to protection. Thus, the study was specif-
ically designed to explore the efficacy of
HIV-specific cytotoxic T cells. A total of
3,000 volunteers with a high risk of
acquiring HIV infection were either im-
munized three times intramuscularly with
replication-deficient adenoviral vectors
transfering the gag, pol, and nef genes of
HIV, or received a placebo. As observed
in non-human primate studies and previ-
ous phase I clinical trials, the adenoviral
vector vaccine induced substantial HIV-
specific cytotoxic T cell responses in most
of the vaccinees [3]. However, at a
planned interim analysis, 19 individuals
in the vaccine arm and 11 individuals of
the placebo arm acquired HIV infection
during a follow-up of approximately 620
person years in both groups [4]. Incidenc-
es of 3.07 and 1.77 per 100 volunteers in
the vaccine and placebo group, respec-
tively, indicate that there was no beneficial
effect of the vaccine on HIV acquisition.
The HIV virus particle transmitted to
an individual cannot be targeted by the
vaccinees’ cytotoxic T cells, because they
require presentation of HIV-derived pep-
tides on autologous MHC-I molecules.
When looking at the different stages in the
establishment of HIV infection after mu-
cosal exposure (Figure 1), the earliest stage
cytotoxic T cells could exert their benefi-
cial effect is the killing of the first HIV-
infected cell, presumably in the lamina
propria of the exposed mucosa. However,
given the low density of T cells in this
compartment, it seems highly unlikely that
an HIV-specific cytotoxic T cell encoun-
ters this single HIV-infected cell. Rather, it
can be assumed that additional replication
cycles and local spread of the virus or
virus-infected cells to the draining lymph
nodes occur prior to encounter with HIV-
specific T cells. Subsequent activation and
expansion of the HIV-specific T cells
might be too slow to prevent further
spread of the virus. Thus, rather then
preventing HIV infection, the benefit of
the cytotoxic T cells might be the
reduction of viral load. However, the
interim analysis of the STEP study also
failed to provide any evidence for lower
viral loads in the vaccine group [4].
Therefore, neither non-neutralizing
gp120-specific antibodies nor HIV-specific
cytotoxic T cells induced by the adenoviral
vector vaccine were sufficient to provide
protection.
The incidence of HIV infections in the
vaccine group seemed to be higher than in
the placebo group. This raised the critical
question of whether vaccination actually
enhances the frequency of HIV acquisi-
tion. Post-hoc analyses of different sub-
groups indicated that the incidence of
HIV infections in volunteers with pre-
existing humoral immunity to adenovirus
prior to immunization was 2.3-fold (95%
confidence interval 1.1 to 4.7) higher than
in the respective placebo subgroup [4]. In
contrast, there was no difference in the
incidence of HIV infection between the
vaccine and the placebo groups in the
absence of pre-existing antibodies to
adenovirus. An initial comparison of the
distribution of risk factors in the vaccine
and placebo subgroups with high levels of
pre-existing adenoviral immunity revealed
a good match of baseline variables such as
location, race, age, risk behavior, circum-
cision, and history of sexual transmitted
diseases [5]. If this holds up for other
confounding factors, the enhanced inci-
dence of HIV infections in this vaccinated
subgroup might have severe implications
for all subsequent HIV vaccine trials, as
well as for vaccine and gene therapy trials
using adenoviral vectors. It is therefore
important to explore how such a vaccine
could increase the susceptibility to HIV
infection. Theoretically, this could be
either due to an excessive adenovirus-
specific immune reaction or due to the
induction of detrimental HIV-specific
immune responses.
Injection of the adenoviral vector par-
ticle can induce an immediate innate
response leading to increased inflammato-
ry cytokine levels in the blood, which
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[6]. However, since the increased HIV
incidence in the vaccine subgroup with
pre-existing adenoviral immunity seems to
persist for at least a year [4], the
immediate innate response is unlikely to
be responsible for the observed increase in
susceptibility to HIV infection in the
vaccine subgroup. Injection of the adeno-
viral particle into individuals with pre-
existing adenoviral immunity also raises a
recall response, including activation of
adenovirus-specific CD4+ T cells. These
activated CD4+ T cells could serve as
additional target cells for HIV in the
lamina propria and therefore enhance
the risk of HIV infection. However, given
the vast amount of antigens and infections
humans are continuously exposed to, it
seems highly unlikely that intramuscular
injection of the adenoviral particle can
notably raise the number of susceptible
CD4+ T cells in the rectal or male genital
mucosa above their pre-existing back-
ground level for an extended period.
Another argument against this hypothesis
is that the percentage of adenovirus-
specific CD4+ T cells in the blood was
actually lower in the group with pre-
existing immunity to adenovirus [3].
Thus, it seems more plausible that HIV-
infected cells or HIV antigen presenting
cells (stages 2 and 3 in Figure 1) activate
vaccine-induced, HIV-specific T cells in
the lamina propria of the exposed mucosa
or in its draining lymph node. In the
absence of effective antiviral effector
mechanisms, these activated HIV-specific
‘‘enhancer’’ T cells could favour early
spread of the HIV infection. Whether this
is only a risk associated with adenoviral
vector vaccines encoding HIV antigens or
is also shared by other HIV vaccines is
unclear. However, two characteristics of
the vaccine used in the STEP study
suggest a note of caution to premature
generalization. First, the enhancement of
HIV infection is only detected in the
presence of pre-existing adenoviral immu-
nity. Thus, the injected adenoviral vector
particle might trigger regulatory events,
which also suppress or modulate as a
bystander effect the HIV-specific T cell
responses induced by the adenoviral
vector-encoded HIV vaccine antigens.
Second, the absence of an Env component
might delay the sensing of the HIV
infection by antibodies (even non-neutral-
izing ones) at an early infection stage,
thereby preventing timely recruitment of
vaccine-induced effector mechanisms to
the early replication sites of HIV. As
neither humoral nor cellular immune
responses alone seem to be sufficient for
protection from HIV, vaccines inducing
both effector arms need to be evaluated. It
seems too early to dispense with the
potential of adenoviral vector-based HIV
vaccines since they are among the most
efficient inducers of cytotoxic T cell
responses in humans and a large number
of animal models.
Whatever the precise mechanism is that
led to enhanced acquisition of HIV
infection in the STEP study vaccine group
with pre-existing adenovirus immunity, it
most likely acts at a stage subsequent to
infection of the first cell in the recipient
individual. The barrier function of the
mucosal epithelia should not be affected
by the intramuscular vaccination. The
number of HIV-susceptible cells in the
lamina propria prior to HIV exposure
should not be enhanced above the pre-
existing background level given the con-
tinous exposure to antigens and frequent
infections with all kinds of pathogens and
commensals. Since all the vaccine antigens
Figure 1. Model of the Early Stages of Mucosal HIV Infection (Modified from [11]) and
Vaccine-Induced Enhancement of Infection. Free virus crosses the epithelial barrier of the
mucosa through breaks or by transport on dendritic cells (DC), transcytosis, or infection of
intraepithelial DC, macrophages, or CD4+ T cells. Initially, this will lead to a single HIV-infected cell
(1) located in the lamina propria. Further spread can be blocked by infection of the first cell with a
replication-deficient virus mutant, integration into a transcriptionally silent genomic region, or
absence of susceptible secondary target cells, leading to abortive infection once the infected cell
dies. If the virus is transmitted to secondary target cells (2), occult infections can occur if the
reproductive rate of HIV-infected cells is reduced to less than one. These occult HIV infections are
reported to be associated with detectable levels of HIV-specific cellular immune responses and
can be defined by transient detection of virus in the absence of subsequent seroconversion.
Transient viremia suggests that occult infections can still occur after spread of the virus to the
regional lymph node (3). As outlined in the text, enhancement of the incidence of established,
seropositive HIV infections in a subgroup of vaccinated volunteers of the STEP study could be
explained by vaccine-induced, HIV-specific enhancer cells (EC) promoting virus spread by acting
on secondary target cells (2) and/or a localized nidus of infection in the draining lymph node (3). If
the enhancer cells indeed increase the number of established HIV infections by acting at stage 2
or 3, early HIV infections must resolve spontaneously in the absence of the vaccine-induced
enhancer cells. An approximate 2-fold increase in the incidence of seropositive HIV infections in
the vaccine subgroup compared to the placebo subgroup therefore suggests that less than half
of all stage 2 or 3 infections in the placebo subgroup progress to established infections.
doi:10.1371/journal.ppat.1000114.g001
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proteins and usually not expressed on the
surface of HIV-infected cells or HIV
particles, only infected recipient cells, but
not the initial virus particle leading to
infection, can trigger the vaccine-induced
enhancer cells to mediate their enhancing
effect.
A likely candidate for these enhancer
cells are vaccine-primed CD4+ T cells re-
activated by HIV peptides presented on
MHC molecules of antigen presenting
cells and/or HIV-infected cells. Since
encounter of a vaccine-induced, HIV-
specific enhancer cell and the first infected
recipient cell seems to be an unlikely
event, the enhancement of infection prob-
ably acts at one of the subsequent rounds
of infection. It is worth noting that
vaccination did not notably enhance viral
load in infected individuals but enhanced
the incidence of infected persons as
diagnosed by seroconversion. If the vac-
cine does not enhance infection at the first
stage, it must enhance the frequency with
which vaccinees progress through subse-
quent stages. This implies that some
unvaccinated individuals must be able to
control transition from the early stages of
infection to later ones. In the absence of
seroconversion, infections that are con-
tained at these early stages are not
diagnosed.
Evidence for the existence of such occult
immunodeficiency virus infections has
come so far from frequently exposed
seronegative individuals (reviewed in
[7,8]) and immunodeficiency virus–ex-
posed non-human primates [9,10]. In the
latter animal models, the monkeys remain
seronegative despite detection of simian
immunodeficiency virus–specific T cell
responses. Furthermore, low levels of viral
RNA can be detected only transiently in
the blood of the exposed animals, indicat-
ing that control of immunodeficiency virus
spread is possible even after production of
substantial amounts of virus particles.
Assuming an unbiased distribution of risk
factors in the vaccine and placebo sub-
groups with pre-existing adenoviral im-
munity, the results of the STEP study
provide further support for the occurrence
of occult HIV infections in humans and
even allow an estimation of the lower limit
of the frequency of occult HIV infections.
An approximate 2-fold increase in the
incidence of seropositive HIV infections in
the vaccine subgroup with pre-existing
adenoviral immunity suggests that at least
half of all early stage HIV infections of the
non-immunized study participants with
pre-existing adenoviral immunity are con-
tained prior to seroconversion. If the
enhancing effect of vaccination does not
mediate progression of all early stage HIV
infections into established HIV infections,
the ratio of occult infections to evident
infections should even be larger than two.
Therefore, occult HIV infections seem to
be much more frequent than generally
assumed. A better understanding of the
determinants of occult infections is urgent-
ly needed and might provide novel
strategies for HIV vaccine development.
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